Search
Dihydrostreptomycin
go.drugbank.com/drugs/DB11512ApprovedVet approvedWithdrawnIn humans, the use of dihydrostreptomycin has been associated with ototoxicity. The FDA withdrew its approval for the use of all drug products containing dihydrostreptomycin sulfate.[L43942]
Sodium tripolyphosphate
go.drugbank.com/drugs/DB11493InvestigationalVet approvedIt is used as a component of a wide range domestic and industrial products, particularly detergents.
Cyclohexanone
go.drugbank.com/drugs/DB02060ExperimentalIt is a colorless, oily liquid with an acetone-like smell. … Cyclohexanone (also known as oxocyclohexane, pimelic ketone, ketohexamethylene, cyclohexyl ketone or ketocyclohexane) is a six-carbon cyclic molecule with a ketone functional group.
Human interferon omega-1
go.drugbank.com/drugs/DB05472InvestigationalIt has been investigated both in single and combination treatment. The biological activities of IFN-omega 1 and its physiological role are not known to date. … It occurs naturally in the human body and is currently being manufactured by Intarcia through genetic engineering.
Nangibotide
go.drugbank.com/drugs/DB16247InvestigationalNangibotide is under investigation in clinical trial NCT04055909 (Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock).
Oxantel
go.drugbank.com/drugs/DB13670InvestigationalOxantel is an anthelmintic drug that targets parasitic acetylcholine receptors.
Fiztasovimab
go.drugbank.com/drugs/DB24033InvestigationalFiztasovimab, also known as NPC‐21 and EV2038, is a monoclonal antibody. … [A278004, A278005] NPC-21 is under investigation in clinical trial NCT04225923 (A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection).
CP-39,332
go.drugbank.com/drugs/DB09193ExperimentalHowever, none of the members of this stereoisomers has been marketed. … It is part of a group of monoamine reuptake inhibitor stereoisomers including tametraline (1R,4S-), CP-24,442 (1S,4R-), CP-22,185 (cis-), and CP-22,186 that show varying efficiency.
Tandutinib
go.drugbank.com/drugs/DB05465InvestigationalThe use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration. Phase I/II trials are underway.